Загрузка...
Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer
Inactivating mutations in either TSC1 or TSC2 cause Tuberous Sclerosis Complex, an autosomal dominant disorder, characterized by multi-system tumor and hamartoma development. Mutation and loss of function of TSC1 and/or TSC2 also occur in a variety of sporadic cancers, and rapamycin and related drug...
Сохранить в:
| Опубликовано в: : | PLoS One |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Public Library of Science
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8064564/ https://ncbi.nlm.nih.gov/pubmed/33891611 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0248380 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|